Comparison of Outcomes Between TransPRK and Off-flap Epi-LASIK

Sponsor
Wenzhou Medical University (Other)
Overall Status
Completed
CT.gov ID
NCT05060094
Collaborator
(none)
38
27.1

Study Details

Study Description

Brief Summary

To compare the quantitative and qualitative optical outcomes between single-step transepithelial photorefractive keratectomy (TransPRK) and off-flap epipolis laser in situ keratomileusis (Epi-LASIK) in moderate to high myopia.we included patients with moderate to high myopia who were randomized to have TransPRK in one eye and Epi-LASIK in the other eye. All patients underwent comprehensive ophthalmological examinations, including uncorrected (UDVA) and corrected distance visual acuities (CDVA), manifest refraction, intraocular pressure, anterior and posterior segment examination, corneal topography measured by Scheimpflug scanning-slit topographer (Pentacam, Oculus Optikgerate GmbH), contrast sensitivity (CS) under photopic and mesopic conditions (CSV-1000E, Vector Vision Inc., Greenville, OH, USA) with correction by spectacles, ocular wavefront aberrometry (OPD-Scan II, Nidek Co. Ltd). At each follow-up, CS and aberration measures were repeated 3 times and the average value was analyzed. Optical parameters were repeated 1, 3, 6, and 12 months after surgery.Statistical analysis was performed using SPSS software (version 22.0, SPSS, Chicago, Inc.). Kolmogorov-Smirnov test was used to check the normal distribution of variables. Student t-test or Wilcoxon rank sum test was used based on the normality of data. A P value less than 0.05 was considered statistically significant.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    38 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Comparison of Outcomes Between Single-step Transepithelial Photorefractive Keratectomy and Off-flap Epipolis Laser in Situ Keratomileusis
    Actual Study Start Date :
    Mar 1, 2016
    Actual Primary Completion Date :
    Mar 1, 2017
    Actual Study Completion Date :
    Jun 5, 2018

    Outcome Measures

    Primary Outcome Measures

    1. aberrations [2016.03.01-2018.06.05]

      ocular high-order aberrations including spherical, coma and trefoil aberrations were measured by OPD-Scan II

    Secondary Outcome Measures

    1. contrast sensitivity [2016.03.01-2018.06.05]

      contrast sensitivity and contrast sensitivity under glare condition measurements were performed by the CSV-1000E which could test four spatial frequencies: 3,6,12 and 18 cycles/degree (cpd) at 2.5m. The contrast sensitivity was measured under photopic (596.7cd/㎡) and scotopic (0.01cd/㎡) conditions and the contrast sensitivity under glare condition was taken under scotopic condition with glare

    2. haze [2016.03.01-2018.06.05]

      Corneal haze grade was recorded according to Fantes's report: 0, no haze; 0.5, trace haze only could be seen by oblique illumination; 1,more visible haze not interfering with the visibility of iris details; 2, mild influence of iris details; 3, moderate influence of iris details; 4, marked haze obscuring the stroma of ablation area.

    3. postoperative pain [2016.03.01-2018.06.05]

      Subjective pain scores were evaluated on the third day according to a predetermined scale ranging from 0 to 5 as follows: 0, no pain or discomfort; 1, photophobia and tears; 2, photophobia and tears with mild pain; 3, photophobia and tears with moderate pain that does not require oral medication; 4, photophobia and tears with severe pain that oral medication can relieve; 5, photophobia and tears with severe pain that oral medication cannot relieve.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years to 38 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • age over 18 years

    • corrected distance visual acuity (CDVA) in logarithm of minimal angle of resolution (LogMAR) of 0.10 or better

    • refractive error stabilized for at least 1 year

    • discontinued contact lens use for at least 2 weeks

    Exclusion Criteria:
    • presence of corneal scars

    • keratoconus

    • glaucoma

    • retinal diseases

    • a history of corneal or intraocular surgery

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Wenzhou Medical University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Yune Zhao, director of cataract department, Wenzhou Medical University
    ClinicalTrials.gov Identifier:
    NCT05060094
    Other Study ID Numbers:
    • outcomes of TransPRK
    First Posted:
    Sep 28, 2021
    Last Update Posted:
    Sep 28, 2021
    Last Verified:
    Sep 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Sep 28, 2021